Related Experiment Video

Updated: Aug 4, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

[Comparison of dinitrate isosorbide retard forms in ischemic heart disease patients with stable effort angina]

V P Lupanov, I A Alekseeva, N N Vasil'eva

    Terapevticheskii Arkhiv
    |November 15, 2000
    PubMed

    Insights

    Cardiket 120 mg once daily is more effective for managing angina than Cardiket 40 mg three times daily. Both isosorbide dinitrate forms were well-tolerated in patients with ischemic heart disease (IHD).

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Ischemic heart disease (IHD) with stable effort angina requires effective management.
    • Isosorbide dinitrate is a common antianginal medication.

    Purpose of the Study:

    • To compare the antianginal and anti-ischemic efficacy and tolerance of two isosorbide dinitrate formulations.
    • Evaluate Cardiket-Retard 120 mg once daily versus Cardiket-Retard 40 mg three times daily in IHD patients.

    Main Methods:

    • An open cross-over study involving 18 IHD patients with stable angina (functional class II and III).
    • Patients received each isosorbide dinitrate formulation for one month.
    • Assessment included anginal attack frequency and exercise tolerance via veloergometry.

    Main Results:

    • Cardiket 120 mg once daily significantly reduced anginal attacks and improved exercise tolerance.
    • Both isosorbide dinitrate formulations were well-tolerated, with no serious side effects reported.

    Conclusions:

    • Cardiket 120 mg once daily demonstrates superior clinical efficiency compared to Cardiket 40 mg three times daily for stable effort angina.
    • Isosorbide dinitrate is a safe and effective treatment option for IHD patients.
    Abstract

    More Related Videos

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

    Published on: February 3, 2021

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

    Published on: April 4, 2022

    Related Concept Videos

    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Angina V: Nursing Management01:20

    Angina V: Nursing Management

    Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...